KIDS earnings analysis
What we found in KIDS's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
OrthoPediatrics reported revenue of $59.4 million for Q1 2026, an increase of 13% from $52.4 million year-over-year. The EPS loss was $0.42, slightly better than the expected loss of $0.43, reflecting positive sales trends in key product segments. Management raised full-year revenue guidance to between $263 million and $267 million, indicating optimism despite ongoing challenges with operating losses.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Growth of 13%
- Q1 2026 revenue was $59.4M, up from $52.4M in Q1 2025, reflecting strong market demand.
- Improved EPS Performance
- Reported diluted EPS was -$0.42, beating estimates of -$0.43 by 2.3%.
- Positive Gross Margin Stability
- Gross margin remained stable at 73%, reflecting effective cost management despite increased sales.
- Strong U.S. Sales Increase
- U.S. sales rose to $45.3M in Q1 2026 from $40.9M in Q1 2025, a growth of 10.8%.
- International Sales Growth
- International revenue also grew from $11.5M to $14.1M, a 22% increase year-over-year.
- Raised Full-Year Revenue Guidance
- Management increased full-year revenue guidance to between $263M and $267M, up from $262M-$266M.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Negative Operating Cash Flow
- Operating cash flow of -$3.3M in Q1 2026, showing persistent cash usage for operations.
- Accumulated Deficit Continues
- Accumulated deficit reached $285.9M, raising concerns about long-term sustainability.
- High Operating Expenses Impact
- Sales and marketing expenses increased by 11%, putting pressure on profitability despite revenue gains.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.42
- Gross margin
- 73%
- Segment
- Trauma and Deformity: $43.0M
- Segment
- Scoliosis: $15.4M
- Segment
- Sports Medicine/Other: $0.9M
What they said about what is next.
Revenue guidance for 2026 raised to $263M-$267M, reflecting optimism in market growth.
The filing reads better than the one before it.
What came before.
- 10-K · March 4, 2026
- OrthoPediatrics reports record 2025 revenue of $236.3 million (up 15% vs. 2024) while continuing to operate at a loss but showing margin and cash-flow improvement late in the year. The company emphasizes its exclusive…
- 10-Q · August 6, 2025
- OrthoPediatrics reported Q2 net revenue of $61.082 million, a 16% increase vs. $52.802 million in Q2 2024, driven by Trauma & Deformity and Scoliosis. Gross margin compressed to 72% from 77% a year ago while GAAP net…
- 10-Q · November 7, 2024
- OrthoPediatrics reported Q3 net revenue of $54.6M, up $14.6M or 37% year-over-year, driven by the Boston O&P acquisition and strength in Trauma & Deformity and Scoliosis. Gross margin compressed to 73% from 77% a year…
- 10-K · March 8, 2024
- OrthoPediatrics Corp. reported total revenue of $148.7 million in 2023, reflecting a significant increase from $122.3 million in 2022, resulting in a compound annual growth rate of 25.0% since 2011. The company…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing KIDS makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever